Sector
PharmaceuticalsOpen
₹80.03Prev. Close
₹80.03Turnover(Lac.)
₹8.34Day's High
₹84.03Day's Low
₹8052 Week's High
₹9652 Week's Low
₹69Book Value
₹35.93Face Value
₹10Mkt Cap (₹ Cr.)
198.78P/E
29.37EPS
2.66Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 23.66 | 23.66 | 23.66 | 23.66 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 57.18 | 49.8 | 38.31 | 33.11 |
Net Worth | 80.84 | 73.46 | 61.97 | 56.77 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 85.14 | 71.21 | 42.47 | 77.2 |
yoy growth (%) | 19.54 | 67.68 | -44.98 | 18.85 |
Raw materials | -39.28 | -36.52 | -19.98 | -38.28 |
As % of sales | 46.13 | 51.28 | 47.05 | 49.58 |
Employee costs | -14.5 | -11.98 | -10.25 | -7.47 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 7.3 | 5.82 | -1.87 | -14.27 |
Depreciation | -5.49 | -4.47 | -3.26 | -3.64 |
Tax paid | 0 | 0 | 0 | -2.17 |
Working capital | -0.75 | 16.58 | 6.23 | -27.03 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 19.54 | 67.68 | -44.98 | 18.85 |
Op profit growth | 11.6 | 738.01 | -124.32 | -3.16 |
EBIT growth | 23.33 | -468.5 | -76.13 | -6.25 |
Net profit growth | -11.59 | -123.11 | 53.2 | -10.93 |
Particulars (Rupees in Crores.) | Mar-2019 | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
---|---|---|---|---|---|
Gross Sales | 43.36 | 47.17 | 64.96 | 85.32 | 97.67 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 43.36 | 47.17 | 64.96 | 85.32 | 97.67 |
Other Operating Income | 0 | 0 | 0 | 0 | 41.11 |
Other Income | 1.66 | 31.33 | 1.14 | 1.98 | 4.9 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,687.6 | 94.57 | 4,05,007.74 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,658 | 80.01 | 1,76,747.65 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,502.4 | 25.22 | 1,21,378.29 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,341.4 | 59.4 | 1,13,184.61 | 474 | 0.96 | 2,385 | 224.33 |
Dr Reddys Laboratories Ltd DRREDDY | 1,301 | 20.3 | 1,08,591.61 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole Time Director
Shanmugam Hemalatha
Non-Exec & Non-Independent Dir
Akilapriya Chandrashekar Raju
Non-Exec. & Independent Dir.
Ravichandran Chitra
Non Executive Director
Upendar Mekala Reddy
Whole-time Director
Vinayak Dinesh Dendukuri
Company Sec. & Compli. Officer
A Mohanachandran
Additional Director
Navin Kumar
Bafna Towers New No 68,
Old No 299 Thambu Chetty St,
Tamil Nadu - 600001
Tel: 91-44-25267517/25270992/4267755
Website: http://www.bafnapharma.com
Email: cs@bafnapharma.com; info@bafnapharma.com
Subramanian Building,
V Floor, 1 Club House Road,
Chennai - 600 002
Tel: 91-044-28460390 (5 L
Website: www.cameoindia.com
Email: cameo@cameoindia.com
Summary
Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing p...
Read More
Reports by Bafna Pharmaceuticals Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.